Furthermore, clinical trials with administration of metformin, which has been shown to regulate mTOR via AMPK, to premalignant lesions of HNSCC have been conducted, and they show promising results as judged by pathologic responses (46). The gene discussed is MTOR; the disease is head and neck squamous cell carcinoma.